These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 25573105)

  • 21. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.
    Wiedmann RT; Reisinger KS; Hartzel J; Malacaman E; Senders SD; Giacoletti KE; Shaw E; Kuter BJ; Schödel F; Musey LK
    Vaccine; 2015 Apr; 33(18):2132-40. PubMed ID: 25796337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
    D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
    Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
    Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
    Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.
    Gans H; Yasukawa L; Rinki M; DeHovitz R; Forghani B; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2001 Oct; 184(7):817-26. PubMed ID: 11528592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
    Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypersensitivity and vaccines: an update.
    Barbaud A; Deschildre A; Waton J; Raison-Peyron N; Tréchot P
    Eur J Dermatol; 2013 Apr; 23(2):135-41. PubMed ID: 23238161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination.
    Dhiman N; Ovsyannikova IG; Ryan JE; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Exp Immunol; 2005 Dec; 142(3):498-504. PubMed ID: 16297162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
    Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison?
    Shoenfeld Y; Aron-Maor A
    J Autoimmun; 2000 Feb; 14(1):1-10. PubMed ID: 10648110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C
    Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.
    Raut SK; Kulkarni PS; Phadke MA; Jadhav SS; Kapre SV; Dhere RM; Dhorje SP; Godse SR
    Clin Vaccine Immunol; 2007 Oct; 14(10):1370-1. PubMed ID: 17699834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
    Yadav S; Thukral R; Chakarvarti A
    Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Güris D; Chaves SS; Schmid S; Seward JF;
    MMWR Recomm Rep; 2007 Jun; 56(RR-4):1-40. PubMed ID: 17585291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.